{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:09:28Z","timestamp":1791050968148,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ahj.2012.12.024","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T23:26:39Z","timestamp":1364340399000},"page":"693-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Thienopyridine efficacy and cigarette smoking status"],"prefix":"10.1016","volume":"165","clinical-trial-number":[{"clinical-trial-number":"nct01260584","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kevin P.","family":"Bliden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2012.12.024_bb0005","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2012.5930","article-title":"Clopidogrel efficacy and cigarette smoking status","volume":"307","author":"Gurbel","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2012.12.024_bb0010","doi-asserted-by":"crossref","first-page":"A62","DOI":"10.1016\/S0735-1097(12)60258-7","article-title":"Differential effect of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the clopidogrel versus aspirin in patients at risk of ischemic events trial","volume":"59","author":"Ferreiro","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0015","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2008.12.044","article-title":"Interaction between cigarette smoking and clinical benefit of clopidogrel","volume":"53","author":"Desai","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0020","first-page":"154e","article-title":"Relationship between clopidogrel and cigarette smoking status in patients with acute coronary syndromes without ST-segment elevation myocardial infarction. Abstract 8","volume":"30","author":"Salek","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ahj.2012.12.024_bb0025","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2012.12.024_bb0030","first-page":"36B","article-title":"Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following PCI","author":"Saraff","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0035","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/CIRCULATIONAHA.109.866533","article-title":"Smoking, clopidogrel, and mortality in patients with established cardiovascular disease","volume":"120","author":"Berger","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ahj.2012.12.024_bb0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1741-7015-9-97","article-title":"The \u201csmoker's paradox\u201d in patients with acute coronary syndrome: a systematic review","volume":"23","author":"Aune","year":"2011","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.ahj.2012.12.024_bb0045","article-title":"Smoker's paradox in young patients with acute myocardial infarction","volume":"29","author":"Chen","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0050","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.12.024_bb0055","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","article-title":"Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis","volume":"49","author":"Buonamici","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0060","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jacc.2008.04.045","article-title":"The association of cigarette smoking with enhanced platelet inhibition by clopidogrel","volume":"52","author":"Bliden","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0065","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.thromres.2009.06.012","article-title":"Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy","volume":"124","author":"Gremmel","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2012.12.024_bb0070","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.amjcard.2009.01.341","article-title":"Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"103","author":"Price","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0075","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1538-7836.2009.03554.x","article-title":"CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring","volume":"7","author":"Aleil","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2012.12.024_bb0080","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/FJC.0b013e31819d616b","article-title":"Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking \u201cParadox\u201d","volume":"53","author":"Motovska","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4070\/kcj.2010.40.3.119","article-title":"The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction","volume":"40","author":"Cho","year":"2010","journal-title":"Korean Circ J"},{"key":"10.1016\/j.ahj.2012.12.024_bb0090","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/j.thromres.2010.03.020","article-title":"Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction","volume":"126","author":"Jeong","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2012.12.024_bb0095","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2012.12.024_bb0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jcin.2011.09.027","article-title":"Cigarette smoking is associated with a dose\u2013response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease","volume":"5","author":"Ueno","year":"2012","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.ahj.2012.12.024_bb0105","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ahj.2010.11.025","article-title":"The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET\/OFFSET and RESPOND studies","volume":"162","author":"Bliden","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.12.024_bb0110","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/heartjnl-2011-301565","article-title":"Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of \u2018smokers' paradox\u2019","volume":"98","author":"Park","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2012.12.024_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.110.034504","article-title":"Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes","volume":"39","author":"Washio","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ahj.2012.12.024_bb0120","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/09537100903046317","article-title":"Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects","volume":"20","author":"Li","year":"2009","journal-title":"Platelets"},{"key":"10.1016\/j.ahj.2012.12.024_bb0125","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0130","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2012.12.024_bb0135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","article-title":"Combination antithrombotic therapies","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.12.024_bb0140","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.12.024_bb0145","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POSTSTENTING Study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0150","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2012.12.024_bb0155","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","author":"Farid","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0160","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2012.12.024_bb0165","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ahj.2012.12.024_bb0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0378-4347(98)00452-6","article-title":"Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography\u2013mass spectrometry","volume":"720","author":"Lagorce","year":"1998","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.ahj.2012.12.024_bb0175","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1124\/jpet.106.110577","article-title":"Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol","volume":"319","author":"Tang","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ahj.2012.12.024_bb0180","unstructured":"Plavix prescribing information. http:\/\/products.sanofi.us\/PLAVIX\/PLAVIX.html. Accessed on 3-5-2012."},{"key":"10.1016\/j.ahj.2012.12.024_bb0185","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/dmd.105.007989","article-title":"Interactions of two major metabolites of prasugrel a thienopyridine antiplatelet agent, with the cytochromes P450","volume":"34","author":"Fayer Rehmel","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ahj.2012.12.024_bb0190","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1124\/dmd.107.020248","article-title":"The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2","volume":"36","author":"Williams","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ahj.2012.12.024_bb0195","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2012.12.024_bb0200","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.12.024_bb0205","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2012.12.024_bb0210","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ahj.2012.12.024_bb0215","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1517\/17425250903107772","article-title":"Recent developments in clopidogrel pharmacology and their relation to clinical outcomes","volume":"5","author":"Gurbel","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0220","first-page":"1","article-title":"The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12)inhibitors","volume":"12","author":"Price","year":"2011","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ahj.2012.12.024_bb0225","unstructured":"FDA drug safety communication. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm203888.htm. Accessed April 6, 2012."},{"key":"10.1016\/j.ahj.2012.12.024_bb0230","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","article-title":"Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance","volume":"109","author":"Lau","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.12.024_bb0235","unstructured":"Effient prescribing information. http:\/\/pi.lilly.com\/us\/effient.pdf. Accessed on 5-3-2012."},{"key":"10.1016\/j.ahj.2012.12.024_bb0240","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.ahj.2012.12.024_bb0245","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1208\/s12248-009-9127-y","article-title":"Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2","volume":"11","author":"Zhou","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.ahj.2012.12.024_bb0250","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2012.12.024_bb0255","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2174\/138920008786049302","article-title":"Clinical pharmacogenetics and potential application in personalized medicine","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ahj.2012.12.024_bb0260","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00228-010-0823-4","article-title":"Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2\u2013163C A polymorphism","volume":"66","author":"Djordjevic","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0265","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1365-2125.2002.01686.x","article-title":"Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2","volume":"54","author":"Han","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(99)70554-8","article-title":"Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers","volume":"117","author":"Fontana","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ahj.2012.12.024_bb0275","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/pgs.09.22","article-title":"Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population","volume":"10","author":"Gunes","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ahj.2012.12.024_bb0280","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0090-9556(24)15013-1","article-title":"Dose-dependent up-regulation of rat pulmonary, renal, and hepatic cytotochrome P-450 (CYP) 1A Expression by nicotine feeding","volume":"27","author":"Iba","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ahj.2012.12.024_bb0285","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.2008.19.3995","article-title":"Overcoming CYP1A1\/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0290","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/FTD.0b013e31819c7037","article-title":"Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study","volume":"31","author":"Ng","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ahj.2012.12.024_bb0295","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0009-9236(95)90052-7","article-title":"Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans","volume":"58","author":"Spigset","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2012.12.024_bb0300","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/03602530903286476","article-title":"Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2","volume":"42","author":"Zhou","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.ahj.2012.12.024_bb0305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2710.2008.00936.x","article-title":"Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel","volume":"33","author":"Yousef","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ahj.2012.12.024_bb0310","first-page":"1069","article-title":"CYP1A2-inducing medications improve platelet responsiveness to clopidogrel","volume":"50","author":"Gengo","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0315","first-page":"131","article-title":"Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test","volume":"9","author":"Tantcheva-Poor","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ahj.2012.12.024_bb0320","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/clpt.2011.70","article-title":"Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility","volume":"90","author":"Dobrinas","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2012.12.024_bb0325","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","article-title":"Time response of cytochrome P450 1A2 activity on cessation of heavy smoking","volume":"76","author":"Faber","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2012.12.024_bb0330","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","article-title":"Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans","volume":"63","author":"Ghotbi","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0335","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-0038-1648859","article-title":"The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A","volume":"72","author":"Savi","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2012.12.024_bb0340","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/0091270009337942","article-title":"Li et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38","volume":"49","author":"Wrishko","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0345","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jacc.2009.08.082","article-title":"Slow response to clopidogrel predicts low response","volume":"55","author":"Bellemain-Appaix","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0350","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/ATVBAHA.110.217182","article-title":"Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status","volume":"31","author":"Park","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0355","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ahj.2011.06.005","article-title":"Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy","volume":"162","author":"Hochholzer","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.12.024_bb0360","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0365","article-title":"Impact of smoking-cessation on platelet inhibition of clopidogrel in patients undergoing elective coronary drug-eluting stent implantation short term smoking cessation","volume":"96","author":"Liu","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2012.12.024_bb0370","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0021-9681(78)90006-1","article-title":"The influence of cigarette smoking on prognosis after a first myocardial infarction. A report from the Framingham study","volume":"31","author":"Sparrow","year":"1978","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ahj.2012.12.024_bb0375","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ahj.2004.01.032","article-title":"Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction\u2013the smoker's paradox revisited","volume":"150","author":"Weisz","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.12.024_bb0380","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/MCA.0b013e3283441d28","article-title":"Impact of smoking on acute phase outcomes of myocardial infarction","volume":"22","author":"Wakabayashi","year":"2011","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.ahj.2012.12.024_bb0385","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ancard.2010.07.006","article-title":"\u201cSmoker's paradox\u201d and reperfusion's strategy in acute myocardial infarction","volume":"59","author":"Addad","year":"2010","journal-title":"Ann Cardiol Angeiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0390","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1056\/NEJM199703133361103","article-title":"Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization","volume":"336","author":"Hasdai","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2012.12.024_bb0395","first-page":"313","article-title":"Acute myocardial infarction in the young\u2013the role of smoking. The Investigators of the International Tissue Plasminogen Activator\/Streptokinase Mortality Trial","volume":"3","author":"Barbash","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2012.12.024_bb0400","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ahj.2010.07.026","article-title":"Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the global registry of acute coronary events","volume":"160","author":"Sibbald","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.12.024_bb0405","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1124\/pr.57.1.3","article-title":"Metabolism and disposition kinetics of nicotine","volume":"57","author":"Hukkanen","year":"2005","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.ahj.2012.12.024_bb0410","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ahj.2012.06.005","article-title":"Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"164","author":"Cornel","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.12.024_bb0415","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.111.032698","article-title":"New horizons in cardioprotection: recommendations from the 2010. National Heart, Lung, and Blood Institute Workshop","volume":"124","author":"Schwartz","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.12.024_bb0420","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/hc3201.094225","article-title":"Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox?","volume":"104","author":"Cohen","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.12.024_bb0425","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2012.12.024_bb0430","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/archinternmed.2011.72","article-title":"Bupropion for smoking cessation in patients with acute coronary syndrome","volume":"171","author":"Planer","year":"2011","journal-title":"Arch Intern Med"},{"issue":"Suppl.","key":"10.1016\/j.ahj.2012.12.024_bb0435","doi-asserted-by":"crossref","first-page":"B17","DOI":"10.1016\/j.jacc.2012.08.064","article-title":"The influence of smoking status on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel: The PARADOX Study Presented at: Transcatheter Cardiovascular Therapeutics 24rd Annual Scientific Symposium (October 22-6) Miami","volume":"60","author":"Gurbel","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.12.024_bb0440","first-page":"A11942","article-title":"Influence of smoking status on the frequency of high platelet reactivity during prasugrel and clopidogrel therapy: analysis from the PARADOX study","volume":"126","author":"Gurbel","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.12.024_bb0445","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"The TRILOGY ACS investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031300149X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031300149X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:49:34Z","timestamp":1757569774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031300149X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S000287031300149X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2012.12.024","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thienopyridine efficacy and cigarette smoking status","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2012.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}